Pfizer Gestion
Gestion contrôle des critères 3/4
Le PDG Pfizer est Albert Bourla, nommé en Jan2019, a un mandat de 7.5 ans. La rémunération annuelle totale est $ 27.59M, composée du salaire de 6.5% et des bonus 93.5%, y compris les actions et options de la société. détient directement 0.007% des actions de la société, d'une valeur de $ 9.49M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6.2 ans et 7.7 ans.
Informations clés
Albert Bourla
Directeur général
US$27.6m
Rémunération totale
| Pourcentage du salaire du PDG | 6.53% |
| Durée du mandat du directeur général | 7.5yrs |
| Propriété du PDG | 0.007% |
| Durée moyenne d'occupation des postes de direction | 6.2yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7.7yrs |
Mises à jour récentes de la gestion
Recent updates
Seeking Alpha • Jun 25
Antibody-Drug Conjugates: Not Quite Worked Out Yet
Summary Pfizer has announced that a late-stage trial in lung cancer for a Seagen-derived ADC, sigvotatug vedotin, has failed. There seems to be no difference in survival for patients treated with this one versus standard chemotherapy. It was targeting a protein found on the vast majority of non-small-cell lung cancer cells, and the Phase I results looked so good that Pfizer skipped right to Phase III to really get things rolling. There are still other clinical trials ongoing with this ADC, and there are certainly other Seagen ADCs in the clinic for Pfizer or heading there. But all this is illustrating that we still don’t know enough about ADCs in general to pick winners. Read the full article on Seeking Alpha
Mise à jour du récit • Jun 22
PFE: Oncology And Obesity Pipeline Progress Will Balance Patent Cliff Risks
Pfizer's analyst price target edges up by $1 to $26, as analysts point to a more balanced risk and reward profile supported by recent guidance commentary, oncology pipeline milestones, and updated views on longer term revenue and margin assumptions. Analyst Commentary Recent research coverage around Pfizer highlights a mix of upgraded ratings, modest price target increases and ongoing questions around specific product exposures and partnership choices.Article d’analyse • Jun 20
Pfizer (PFE) Stock Could Be 10% Undervalued After CFO Exit Raises Execution Questions
Pfizer (PFE) is back in focus after the company said Chief Financial Officer Dave Denton will leave in August, with long-time finance executive Cecile Guegan stepping in as interim CFO during the search for a successor. See our latest analysis for Pfizer. The CFO announcement comes as Pfizer shares trade at US$25.21, with the stock down over the past quarter but posting a 12.52% total shareholder return over the last year. This suggests that shorter term momentum has cooled even as income and...
Mise à jour du récit • Jun 08
PFE: Oncology And Obesity Pipeline Will Support Post Patent Cliff Repricing
Narrative update Pfizer's analyst price targets have inched higher, with a recent move such as Wolfe Research lifting its view to $26 from $25 as analysts factor in elements like the five-year sales outlook and extended Vyndamax exclusivity, while also accounting for COVID-related uncertainty in their updated assumptions. Analyst Commentary Recent Street commentary on Pfizer centers on two themes investors should keep in mind: how analysts are framing post COVID revenue visibility and how legal and partnership developments may affect long term cash flow and valuation support.
Mise à jour du récit • May 25
PFE: Obesity And Oncology Pipeline Progress Will Drive Long-Term Upside Potential
Analysts have nudged Pfizer's implied fair value slightly higher to about $29.19 per share, reflecting a series of mostly modest price target increases, including Wolfe Research's move to $26. This comes alongside updated views on long term sales, COVID uncertainty, patent settlements around Vyndamax, and the recent Veppanu licensing, as well as GLP-1 and oncology pipeline commentary.Mise à jour du récit • May 03
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post Settlement Outlook
Pfizer's updated analyst price target has shifted slightly lower to $24.00 from $25.00 as analysts factor in a steeper projected revenue decline, a modestly higher profit margin outlook, and mixed views on the post-settlement pipeline and patent overhang. Analyst Commentary Recent research on Pfizer highlights a split view.Mise à jour du récit • Apr 19
PFE: GLP-1 And Oncology Advancements Will Support Post LOE Repricing
Pfizer's analyst fair value estimate has been adjusted modestly higher to $35.96 from $35.33, as analysts factor in recent price target raises and mixed views on the post-2028 pipeline, loss of exclusivity risks, and evolving expectations for the GLP-1 and oncology portfolios. Analyst Commentary Recent Street research on Pfizer reflects a split view, with some firms expressing caution around patent expiries and near term visibility, while other bullish analysts focus on the potential in GLP-1 and oncology programs, along with broader sector appeal in healthcare.Mise à jour du récit • Apr 05
PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating
Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.Mise à jour du récit • Mar 22
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post 2028 Outlook
Pfizer's updated analyst narrative keeps fair value steady at $25.00, with recent Street research showing price targets clustering from $25.00 to $35.00 as analysts weigh concerns about a post-2028 patent cliff against interest in the GLP-1, oncology, and collaboration pipelines, as well as healthcare's perceived appeal in a riskier macro backdrop. Analyst Commentary Recent Street research around Pfizer reflects a split view, with some firms pointing to potential in GLP-1, oncology, hematology, and collaborations, while others emphasize the scale and timing of the expected revenue cliff and limited visibility on offsets.Mise à jour du récit • Mar 08
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Next Decade
Analysts lifted their fair value estimate for Pfizer from $23.00 to $25.00 per share, reflecting updated views that weigh a stronger GLP 1 and oncology pipeline against ongoing concerns about the patent cliff and near term revenue visibility. Analyst Commentary Recent Street research on Pfizer presents a mixed picture, with more cautious voices focusing on patent expirations, limited near term pipeline visibility, and questions around how quickly new therapies can support growth.Mise à jour du récit • Feb 21
PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating
Pfizer's updated analyst price target edges lower to about $35 per share. This reflects analysts' focus on ongoing losses of exclusivity, a slightly softer revenue and margin outlook, and tempered expectations for future P/E as some firms initiate or assume coverage with more cautious views around the next few years.Mise à jour du récit • Feb 07
PFE: Obesity Pipeline And LOE Headwinds Will Shape Future Re Rating
Narrative Update Analysts have trimmed their fair value estimate for Pfizer from $36.16 to $35.46, reflecting more cautious assumptions on revenue trends and profit margins, even as some on the Street highlight new assets and deals that they believe could support a higher future P/E multiple. Analyst Commentary Recent Street research on Pfizer highlights a mix of caution and optimism, with several firms reassessing how the pipeline and recent deals might offset upcoming patent expiries and support the valuation over time.Mise à jour du récit • Jan 24
PFE: Loss Of Exclusivity And Obesity Deal Costs Will Pressure Shares
Analysts have reduced their fair value estimate for Pfizer from $24.00 to $23.00 per share, citing lower revenue and margin assumptions, a slightly higher discount rate, and cautious views on patent expiries, while still noting ongoing interest in its pipeline and licensing deals. Analyst Commentary Recent Street research around Pfizer has been mixed, with some firms highlighting long term opportunities in areas like obesity and licensing, while others are stressing near term execution and patent expiry risks.Mise à jour du récit • Jan 10
PFE: Obesity Deal And LOE Overhang Will Shape Re Rating Potential
Analysts have trimmed their price expectations for Pfizer, citing ongoing revenue uncertainty around an expected US$15b to US$20b loss of exclusivity over the next few years, even as some see support from the obesity deal and a broader positive stance on large cap biopharma. Analyst Commentary Recent research highlights a split view on Pfizer, with some caution around the expected US$15b to US$20b loss of exclusivity over the next few years and others pointing to potential upside linked to obesity treatments and a broader positive stance on large cap biopharma.Article d’analyse • Jan 08
Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43
Pfizer Inc. ( NYSE:PFE ) will pay a dividend of $0.43 on the 6th of March. This makes the dividend yield 6.8%, which...Mise à jour du récit • Dec 25
PFE: Obesity Bid And Margin Outlook May Drive Re-Rating Ahead
Analysts have nudged their price target on Pfizer higher by $2 to $30, citing improving margin expectations and a more constructive sector backdrop, despite tempered revenue growth assumptions. Analyst Commentary Bullish analysts highlight that the latest price target increase reinforces a gradually improving sentiment toward Pfizer, with investors starting to look past the near term revenue slowdown and focus more on medium term cash flow durability and pipeline execution.Article d’analyse • Dec 18
Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43
The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will pay a dividend of $0.43 per share on the 6th of March...Mise à jour du récit • Dec 11
PFE: Obesity Pipeline Expansion Will Drive Upside Amid Sector Rerating
Analysts nudged their price target on Pfizer higher to $30 from $28, citing a sector wide rerating on benign U.S. drug pricing developments and the strategic upside from an expanded obesity pipeline and broader large cap biopharma innovation. Analyst Commentary Bullish analysts highlight that Pfizer is benefiting from a constructive shift in U.S. drug pricing expectations and a broader rerating of large cap biopharma, which supports the recent price target increase and stabilizes valuation multiples.Mise à jour du récit • Nov 13
PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts
Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.Article d’analyse • Aug 12
Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business
NYSE:PFE 1 Year Share Price vs Fair Value Explore Pfizer's Fair Values from the Community and select yours Pfizer...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 29 2026 | n/a | n/a | US$7b |
| Dec 31 2025 | US$28m | US$2m | US$8b |
| Sep 28 2025 | n/a | n/a | US$10b |
| Jun 29 2025 | n/a | n/a | US$11b |
| Mar 30 2025 | n/a | n/a | US$8b |
| Dec 31 2024 | US$25m | US$2m | US$8b |
| Sep 29 2024 | n/a | n/a | US$4b |
| Jun 30 2024 | n/a | n/a | -US$3b |
| Mar 31 2024 | n/a | n/a | -US$288m |
| Dec 31 2023 | US$22m | US$2m | US$2b |
| Oct 01 2023 | n/a | n/a | US$10b |
| Jul 02 2023 | n/a | n/a | US$21b |
| Apr 02 2023 | n/a | n/a | US$29b |
| Dec 31 2022 | US$33m | US$2m | US$31b |
| Oct 02 2022 | n/a | n/a | US$30b |
| Jul 03 2022 | n/a | n/a | US$29b |
| Apr 03 2022 | n/a | n/a | US$25b |
| Dec 31 2021 | US$24m | US$2m | US$22b |
| Oct 03 2021 | n/a | n/a | US$19b |
| Jul 04 2021 | n/a | n/a | US$12b |
| Apr 04 2021 | n/a | n/a | US$9b |
| Dec 31 2020 | US$21m | US$2m | US$7b |
| Sep 27 2020 | n/a | n/a | US$212m |
| Jun 28 2020 | n/a | n/a | US$7b |
| Mar 29 2020 | n/a | n/a | US$9b |
| Dec 31 2019 | US$18m | US$2m | US$11b |
Rémunération vs marché: La rémunération totale de Albert ($USD 27.59M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 14.71M ).
Rémunération et revenus: La rémunération de Albert a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Albert Bourla (64 yo)
7.5yrs
Titularisation
US$27,585,301
Compensation
Dr. Albert Bourla, DVM, Ph.D. serves as Chairman & CEO at Pfizer Venture Investments LLC. He serves as CEO from January 2019. He serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 a...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman of the Board & CEO | 7.5yrs | US$27.59m | 0.0069% $ 9.5m | |
| Executive VP & CFO | 4.2yrs | US$9.67m | 0.00067% $ 918.4k | |
| Chief Scientific Officer and President of Research & Development | 1.5yrs | US$10.01m | 0.0028% $ 3.9m | |
| Executive VP & Chief Legal Officer | 12.6yrs | US$9.11m | 0.0029% $ 4.0m | |
| Executive VP & Chief U.S. Commercial Officer | 4.9yrs | US$9.43m | 0.00052% $ 712.8k | |
| Senior VP | 6.3yrs | pas de données | 0.00055% $ 753.9k | |
| Executive VP & Chief Information Officer | less than a year | pas de données | 0.00083% $ 1.1m | |
| Chief Investor Relations Officer | no data | pas de données | pas de données | |
| Chief People Experience Officer & Executive VP | 6.1yrs | pas de données | 0.00074% $ 1.0m | |
| Senior VP and Chief Scientific Officer of Inflammation & Immunology | 10.2yrs | pas de données | pas de données | |
| Chief Scientific Officer of Oncology | 7yrs | pas de données | pas de données | |
| Senior VP & Chief Scientific Officer of Rare Disease | no data | pas de données | pas de données |
6.2yrs
Durée moyenne de l'emploi
60yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de PFE est chevronnée et expérimentée (6.2 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman of the Board & CEO | 6.5yrs | US$27.59m | 0.0069% $ 9.5m | |
| Independent Director | 6.3yrs | US$380.52k | 0.000060% $ 82.2k | |
| Lead Independent Director | 12.8yrs | US$410.00k | pas de données | |
| Independent Director | 9.4yrs | US$360.00k | 0.00057% $ 781.3k | |
| Independent Director | 18.8yrs | US$410.00k | 0.00018% $ 246.7k | |
| Independent Director | 12.1yrs | US$390.00k | 0.000060% $ 82.2k | |
| Independent Director | 1.8yrs | US$360.00k | pas de données | |
| Independent Director | 8.3yrs | US$380.00k | pas de données | |
| Independent Director | 6.4yrs | US$380.00k | pas de données | |
| Independent Director | 2.1yrs | US$380.00k | 0.00018% $ 246.7k | |
| Independent Director | 7.1yrs | US$393.50k | 0.00018% $ 246.7k | |
| Independent Director | 11.1yrs | US$400.37k | pas de données |
7.7yrs
Durée moyenne de l'emploi
65yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de PFE sont considérés comme expérimentés (ancienneté moyenne 7.7 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/09 03:55 |
| Cours de l'action en fin de journée | 2026/07/09 00:00 |
| Les revenus | 2026/03/29 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Pfizer Inc. est couverte par 44 analystes. 25 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |